BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Phase 3

Completed

Conditions: Hormone Refractory Prostate Cancer
Bone Metastases

Interventions: Drug: Placebo
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
Drug: Best standard of care (BSoC)

First Posted Date: 2008-06-18

Last Posted Date: 2016-05-27

Lead Sponsor: Bayer

Target Recruit Count: 921

Registration Number: NCT00699751

Mirena Efficiency and Tolerability During the First Year of Use

Phase 4

Completed

Conditions: Medicated Intrauterine Devices
Contraception

Interventions: Drug: Mirena (BAY86-5028)

First Posted Date: 2008-06-12

Last Posted Date: 2014-12-31

Lead Sponsor: Bayer

Target Recruit Count: 199

Registration Number: NCT00696202

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Phase 2

Active, not recruiting

Conditions: Hypertension, Pulmonary

Interventions: Drug: Riociguat (Adempas, BAY63-2521)

First Posted Date: 2008-06-11

Last Posted Date: 2024-12-16

Lead Sponsor: Bayer

Target Recruit Count: 22

Registration Number: NCT00694850

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

Phase 3

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Nexavar (Sorafenib, BAY43-9006)
Drug: Placebo

First Posted Date: 2008-06-06

Last Posted Date: 2018-08-08

Lead Sponsor: Bayer

Target Recruit Count: 1114

Registration Number: NCT00692770

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Fast & Fed Pharmacokinetic (PK) Study

Phase 1

Completed

Conditions: Bioavailability

Interventions: Drug: Naproxen sodium

First Posted Date: 2008-06-06

Last Posted Date: 2013-05-03

Lead Sponsor: Bayer

Target Recruit Count: 32

Registration Number: NCT00692016

Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.

Phase 3

Completed

Conditions: Pelvic Inflammatory Disease

Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039)
Drug: Ofloxacin

First Posted Date: 2008-05-26

Last Posted Date: 2014-10-15

Lead Sponsor: Bayer

Target Recruit Count: 749

Registration Number: NCT00683865

Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks

Phase 3

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Placebo
Drug: Levitra (Vardenafil, BAY38-9456)

First Posted Date: 2008-05-21

Last Posted Date: 2013-10-14

Lead Sponsor: Bayer

Target Recruit Count: 383

Registration Number: NCT00682019

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis

Phase 3

Completed

Conditions: Brain Neoplasms

Interventions: Drug: Magnevist (SH L 451A)

First Posted Date: 2008-05-21

Last Posted Date: 2014-12-15

Lead Sponsor: Bayer

Target Recruit Count: 45

Registration Number: NCT00681551

Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction

Phase 4

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Levitra (Vardenafil, BAY38-9456)

First Posted Date: 2008-05-21

Last Posted Date: 2014-12-11

Lead Sponsor: Bayer

Target Recruit Count: 333

Registration Number: NCT00681772

Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID

Phase 1

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: Riociguat (Adempas, BAY63-2521)

First Posted Date: 2008-05-20

Last Posted Date: 2015-12-16

Lead Sponsor: Bayer

Target Recruit Count: 7

Registration Number: NCT00680654

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy